detectiome

Detectiome, founded in 2022 by Arman Vali and Dr. Soheil Damangir, is a precision medicine company based in Dubai, United Arab Emirates, operating within the diagnostic equipment and biotechnology sectors. The firm is addressing a critical gap in cancer screening by developing liquid biopsy technology specifically tailored to the genetic diversity of the Middle Eastern population. This focus was driven by the observation that precision diagnostic tools developed on Western populations can see their effectiveness drop by up to 50% when used for other ethnicities.

The company's business model centers on providing its proprietary multi-cancer early detection (MCED) test, named Revonco, to healthcare providers. This product is designed to be a scalable, cost-effective blood test for clinics, hospitals, and concierge medicine services, enabling them to offer advanced cancer screening. Revonco was officially launched at the Expand North Star event in October 2023. As of that time, the test was available for research use only, with plans for clinical trials and pilot studies before seeking approval from the UAE's Ministry of Health and Prevention for public use.

Detectiome's core product, Revonco, is a blood test that leverages a combination of generative artificial intelligence, multiomics (including genomics, epigenomics, and transcriptomics), and bioinformatics to detect subtle changes in a patient's epigenome. This allows for the simultaneous detection of up to 15 prevalent cancers, often before any symptoms appear. A key differentiator is that its AI models are trained on data specific to the Middle East's population, aiming for higher accuracy and reducing the biases found in other tests. By identifying cancers at their earliest stages, the technology aims to significantly improve treatment outcomes and survival rates.

The company is a part of the in5 incubator ecosystem and has received backing from the Mohammed Bin Rashid Innovation Fund. Detectiome has been recognized for its work, receiving the Healthtech Startup of the Year at the Enterprise Agility Awards in 2022 and the Most Impactful Business award from the Mohammed Bin Rashid Innovation Fund.

Keywords: multi-cancer early detection, liquid biopsy, precision medicine, AI diagnostics, cancer screening, epigenetic analysis, Middle East healthcare, Revonco, bioinformatics, genomics, early cancer detection, diagnostic equipment, biotechnology, genetic diversity, population health, clinical trials, UAE healthtech, non-invasive diagnostics, oncology technology, personalized medicine